Full TitleA Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants with Multiple Myeloma
The purpose of this study it to assess the safety of giving the investigational drug teclistamab in combination with other treatments in people with multiple myeloma that has come back or continued to grow despite prior therapy. Teclistamab is type of drug called a “bispecific antibody.” It binds to a protein found on the surface of myeloma cells and another protein on the surface of immune system cells called T cells. Researchers think teclistamab may activate T cells to target and destroy myeloma cells.
Patients will receive one of five different treatment regimens:
- Group 1: teclistamab plus daratumumab and pomalidomide
- Group 2: teclistamab plus daratumumab, lenalidomide, and bortezomib
- Group 3: teclistamab plus nirogacestat
- Group 4: teclistamab plus lenalidomide
- Group 5: teclistamab plus daratumumab and lenalidomide
Teclistamab and daratumumab are given as a subcutaneous (under the skin) injection and the other medications are taken orally (by mouth).
To be eligible for this study, patients must meet several requirements, including:
- Participants must have multiple myeloma that continues to grow despite treatment.
- The serious side effects of prior therapies must get better before receiving the study treatment.
- Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
- This study is for people age 18 and older.
For more information about this study and to ask about eligibility, please contact the office of Dr. Carlyn Tan at 646-608-3778.